BioInvent (STO: BINV): KOL Event to Drive Visibility

Using our interactive virtual platform, LifeSci hosted a total of 166 attendees, including institutional investors, sell-side analysts, bankers, high net worth investors, and strategics. The discussion addressed BioInvent’s clinical update on BI-1206 for Relapsed or Refractory Non-Hodgkin's Lymphoma

BioInvent became a LifeSci Advisors client in 2016. The teams collaborated to develop and execute a robust, best-in-class investor relations program to engage the investment community.


  • The event featured a presentation by renowned lymphoma expert Mats Jerkeman MD, Lund University, who discussed the current treatment landscape, and unmet medical need for patients with relapsed or refractory Non-Hodgkin’s Lymphoma for whom current treatment options are very limited.
  • BioInvent’s management team also gave an update on their ongoing Phase I/II trial of BI-1206 in combination with rituximab and BioInvent’s partner CASI Pharmaceuticals (NASDAQ: CASI) provided an update on the development plan and potential for BI-1206 in China.


Using our interactive virtual platform, the discussion addressed BioInvent’s clinical update on BI-1206 for Relapsed or Refractory Non-Hodgkin’s Lymphoma. Following the Event BioInvent went on to offer a direct share issue. Through the directed share issue, BioInvent receives proceeds amounting to approximately SEK 962 million (approximately USD 116 million) before transaction costs.



“The LifeSci team has a very pro-active approach and work as if they were an integral part of the company. Their marketing across the US, Europe and Israel has been effective in increasing our visibility with high quality institutional investors. LifeSci recently organised a KOL event which was perfectly timed ahead of our directed share issue. The event preparation process was seamless and resulted in an impressive audience of investors and sell-side analysts. LifeSci KOL events are a valuable resource for promoting third-party scientific validation.” Martin Welschof, BioInvent CEO